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cating that many V1 neurons project to both pale
and thick stripes (Fig. 3, F to I). By contrast,
paired tracer injections (n 5 2) in adjacent thin
and pale stripes revealed virtually no double-
labeled cells. Thus, the V1 projections from
interpatches to pale and thick stripes arise from
a common source, although most neurons do
project exclusively to either a pale stripe or a
thick stripe.
The V2 tracer injections revealed novel pro-
jections from other cortical layers. Layer 4A is
the thinnest layer in V1 (,50 mm thick), re-
ceives a direct projection from the parvocellular
system, and has a characteristic cytochrome ox-
idase honeycomb pattern (26). It sent a dual
pattern of projections to V2. Thick and pale
stripe injections produced 4A label in interpatch
columns [Web fig. 1A (27)]. Thin stripe injec-
tions resulted in 4A label that coincided with
patch columns [Web fig. 1B (27)]. This projec-
tion from layer 4A adds a second potential
disynaptic route from the geniculate to V2: par-
vocellular3 layer 4A3 V2, in addition to the
known koniocellular3 patches3 V2 pathway
(28). Injections in all stripes labeled numerous
large neurons, often Meynert cells, near the
layer 5/6 border. These cells were distributed
indiscriminately with respect to patches and in-
terpatches.
These findings recast the V1-to-V2 pathway.
Previous studies found projections arising from
only single layers, organized in a tripartite fash-
ion: layer 2/3 patches 3 thin stripes, layer 2/3
interpatches 3 pale stripes, and layer 4B 3
thick stripes (6, 7). It has subsequently been
recognized that considerable mixing of magno,
parvo, and konio geniculate channels occurs
within V1 (29). However, the apparent exis-
tence of three distinct, partitioned V1 projec-
tions to thick, pale, and thin stripes implied that
three channels—dominated by magno, parvo,
and konio inputs—survived after processing
within V1. We now show that thick, thin and
pale stripes all receive projections from the
same V1 layers: heaviest from layer 2/3 and less
from layers 4A, 4B, and 5/6. The dominant
theme is not tripartite, but bipartite segregation
defined by cytochrome oxidase columns: patch-
es3 thin stripes, and interpatches3 pale and
thick stripes (Fig. 4). These anatomical data
explain the relatively poor segregation of recep-
tive field properties in pale and thick stripes
found by some investigators (30–32). Our re-
sults provide a new connectional foundation for
the cortical hierarchy of visual areas (16, 33).
They suggest a rich intermingling of form, col-
or, and motion signals between the streams
bound for the dorsal “where” and ventral “what”
pathways (17, 34).
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Placebo and Opioid Analgesia—
Imaging a Shared Neuronal
Network
Predrag Petrovic,1 Eija Kalso,2 Karl Magnus Petersson,1 Martin Ingvar1*
It has been suggested that placebo analgesia involves both higher order cognitive
networks and endogenous opioid systems. The rostral anterior cingulate cortex
(rACC) and the brainstem are implicated in opioid analgesia, suggesting a similar
role for these structures in placebo analgesia. Using positron emission tomography,
we confirmed that both opioid and placebo analgesia are associated with increased
activity in the rACC. We also observed a covariation between the activity in the
rACC and the brainstem during both opioid and placebo analgesia, but not during
the pain-only condition. These findings indicate a related neural mechanism in
placebo and opioid analgesia.
Placebo analgesia is an important component
in pain management (1), although the basic
mechanisms are still poorly understood. At
least some aspects of placebo analgesia are
dependent upon endogenous opioid systems
(1–3) because the effect may be partly abol-
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ished by the opioid antagonist naloxone (2).
Therefore, the underlying neurophysiology of
opioid-dependent placebo analgesia can be elu-
cidated by studying similarities and differences
in the function of the opioid and placebo sys-
tems in the brain. The opioid system consists of
a well-studied subsystem in the brainstem and a
less well elaborated cortical opioid-dependent
network (4, 5). This system appears to be a
likely candidate for the mediation of opioid-
dependent placebo analgesia. The importance
of the ACC in opioid effects has been suggested
in several receptor-imaging studies of the brain
(6–10), activation studies of opioid compounds
(11–14), and theoretical frameworks of opioid
analgesia (15). The rostral ACC (rACC)/ven-
tromedial prefrontal cortex has been suggested
as an important region in opioid analgesia and
in other forms of pain modulation (16–26),
which may suggest a similar involvement of
higher order control of opioid-dependent place-
bo analgesia.
We compared the analgesic effects of a
placebo treatment and a rapidly acting opioid
(remifentanil) [supplement A (27)] in a stan-
dard pain-stimulus paradigm (28). We used
six different conditions in the study: heat pain
and opioid treatment (POP), nonpainful
warm stimulation and opioid treatment
(WOP), heat pain and placebo treatment
(PPL), nonpainful warm stimulation and pla-
cebo treatment (WPL), heat pain only (P),
and nonpainful warm stimulation only (W).
We studied concomitant behavioral responses
and regional cerebral blood flow (rCBF) us-
ing positron emission tomography (PET) (29,
30) and compared the functional anatomy of
the placebo analgesic response with that of
the opioid response. We were especially in-
terested in whether placebo analgesia and
opioid effects induce a similar rCBF response
in the rACC and the brainstem.
Comparison of scans in the pain condi-
tions and in the warm conditions showed
increased activity in the contralateral thala-
mus, in the insula bilaterally, and in the cau-
dal ACC [Web table 1 (27) and Fig. 1A], all
regions that have shown increased activity in
previous imaging studies of pain (31). The
opioid agonist remifentanil activated the ce-
rebral network [Web table 2 (27) and Figs.
1B and 2A], which has been described pre-
viously in opioid receptor binding (6–9) and
in rCBF studies (11–14). One of the major
increases in rCBF was observed in the ACC
and especially in the rACC. We also observed
an increased activity in the lower brainstem.
The subjects rated the pain intensity lower
during POP compared with P in every exper-
imental block [Web fig. 1 (27)]. The rCBF
analysis showed that the insula, one of the
major regions involved in pain processing,
had an attenuated rCBF response bilaterally
during POP-WOP as compared with P-W
[Web table 2 (27)].
Although there was high interindividual
variability in placebo ratings, most subjects de-
creased their pain intensity rating during PPL as
compared with the P condition [Web fig. 1
(27)]. Recent experiments have revealed differ-
ent types of placebo analgesia and indicate that
some are dependent upon opioid systems (32,
33). Placebo responses were induced in subjects
1Cognitive Neurophysiology Research Group, Depart-
ment of Clinical Neuroscience, Karolinska Institute,
Stockholm 171 76, Sweden. 2Pain Clinic, Department
of Anaesthesia and Intensive Care Medicine, Helsinki
University Hospital, Finland.
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Fig. 1. (A) Increased
activity was observed
in the right (cross) and
left insula (left panel,
horizontal section), in
the thalamus (left
panel), and in the cau-
dal ACC (right panel,
sagittal section) dur-
ing the main effect of
pain [(POP 1 PPL 1
P)-( WOP 1 WPL 1
W )]. (B) The activa-
tion was most pro-
nounced in the rACC
during the main effect
of opioids [(POP 1
WOP)-(P 1 W )]. In-
creased activity is ap-
parent in the lower
pons. (C) Increased ac-
tivity in the same area
of the rACC was also
seen in the placebo effect during pain (PPL-P). The activations are presented on an SPM99-
template. The activation threshold is at P 5 0.005.
Fig. 2. (A) The main
effect of remifentanil
[(POP 1 WOP)-(P 1
W )] showed increased
activity bilaterally in







and lower pons. The
effect was widespread
in the rACC and bilat-
erally in the anterior
insula. (B) The placebo
effect during pain (PPL-P) showed increased activity in the orbito-
frontal regions bilaterally (most extensively in the right hemisphere)
and in the contralateral rACC. (C) To observe the overlapping acti-
vation in the two different conditions, we used the placebo analgesia
effect (activation threshold at P 5 0.001) and masked the main effect
of remifentanil (same activation threshold). Several of the orbitofron-
tal regions in the right hemisphere and in the rACC remained after the
high-threshold masking, indicating that these regions were activated
both during opioid stimulation and during the pain and placebo
conditions. Thus, these regions were activated both by opioids in
general and by placebo during pain. The activations are presented on
an SPM99-template. The activation threshold is at P 5 0.005.
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as a result of suggestions that each of the drugs
used in the experiment was a potent analgesic
(28) (i.e., expectation of pain relief ) and by
preceding the placebo treatment by active opi-
oid during noxious stimulation in the first (five
subjects) or second experimental block (four
subjects) (i.e., opioid conditioning). Both of
these placebo mechanisms can be abolished by
the opioid antagonist naloxone and thus appear
to be opioid dependent (32). Therefore, we
expected similarities between activity observed
in the opioid network and in the placebo anal-
gesia network. The placebo analgesia was ac-
companied by increased activity in the orbito-
frontal and ACC areas during PPL when com-
pared with P [Web table 3 (27); Figs. 1C and
2B]. When we controlled for unspecific placebo
effects (WPL-W), we observed an activation in
the ACC [Web table 3 (27)], somewhat caudal
to the rACC effect in PPL-P but rostral to the
ACC activation during pain.
Previous imaging studies have shown that
the rACC is more reliably activated by opi-
oids, whereas the caudal ACC is more reli-
ably activated by pain (11, 12). This distinc-
tion was also observed here, pointing to the
importance of the rACC in opioid analgesia.
This area of the human ACC contains a high
concentration of opioid receptors (9). More-
over, studies examining stimulus-induced an-
algesia (16, 18, 19, 21, 23), nitrous oxide–
induced analgesia (22), and hypnosis-induced
change in pain perception (24, 25) have
shown an increased activation in the rACC
associated with the modulation mechanism.
Rainville et al. (25) noted a similar functional
division of the ACC: Pain (and unpleasant-
ness) activated a more caudal region in the
ACC, whereas the conditions involving sug-
gestion, resulting in modulation of the pain
experience, activated a more rostral part in
the ACC. Hence, the increased activity in the
rACC during PPL-P may support its involve-
ment in the analgesic response mechanism
during placebo. In addition, a post hoc anal-
ysis indicated that during opioid analgesia,
the high placebo responders activated this
area, whereas the low responders did not
(Fig. 3). This suggests a relation between
how effectively opioids may activate the
rACC and adjacent areas and how well sub-
jects respond to placebo during pain. Earlier
studies have shown a behavioral correlation
between opioid analgesia and placebo anal-
gesia (32). The suggestion that the opioid
system may vary among subjects is supported
by the finding that the opioid receptor bind-
ing potential during rest and pain is highly
specific to an individual (10), leading to the
hypothesis that high placebo responders have
a more efficient opioid system.
The placebo analgesic effect is dependent
on complex cognitive information process-
ing, including analysis of threat in a given
context, expectations of treatment outcome,
and desire for relief (1, 3, 4). The brainstem
opioid system may thus be under cognitive
control from higher order cortical regions.
The ACC might play a key role in the cortical
control of the brainstem during opioid anal-
gesia (15, 34) by way of fiber tracts project-
ing directly to the periaqueductal gray (PAG)
(35) or by way of the medial thalamic nucleus
(36). A similar mechanism may be necessary
in placebo analgesia, which implies that a
functional connection should exist between
these regions, both in opioid and placebo
analgesia. Regression analysis supported this
hypothesis (30) [Web table 4 (27) and Fig.
4]. The activity in the rACC covaried with
activity in areas close to the PAG and the
pons in the POP condition. We also observed
a significant covariation in activity between
the rACC and the pons, and a subsignificant
covariation in activity between the rACC and
the PAG, during PPL. No effect was ob-
served in the pain-only condition (P), and the
differences between these regressions (POP
versus P and PPL versus P) were significant.
The area in the pons is in the same region as
the area activated in the main effect of opi-
oids (Fig. 1). The brainstem opioid system
consists of the PAG, which alters the neuro-
nal activity in the rostral ventromedial me-
dulla (4, 5). Additional nuclei in the pons,
such as the parabrachial nuclei, also contain
opioid-dependent neurons (4, 5). The positive
covariation between rACC and these regions
during POP and PPL, but not during P, may
thus indicate that the higher cortical systems
may, in specific circumstances, exert direct
control over the analgesic systems of the
brainstem not only during opioid analgesia
but also during placebo analgesia.
The increased activity in the lateral orbito-
frontal cortex during placebo analgesia is of
interest because previous PET studies have
implicated this region in cognitively driven
pain modulation (25, 37). Stimulation of this
region in rats (38) and primates (39) also
induces analgesia. A right predominance of
the orbitofrontal activation was observed dur-
ing placebo analgesia, but interpretation of
this finding is uncertain because it may re-
flect a threshold effect. Placebo analgesia
Fig. 3. Post hoc analy-
sis comparing the ac-
tivation of the rACC in
high placebo respond-
ers with that in low
responders revealed
no signiÞcant differ-
ences in PPL-P be-
tween groups. Howev-
er, activation of the
rACC and adjacent ar-
eas by the high place-
bo responders was signiÞcant during POP-P [(x, y, z) 5 (22, 46, 22); Z 5 4.77] (A), whereas
activation by the low responders was not signiÞcant (B). The difference between groups was
signiÞcant in the rACC/ventromedial prefrontal cortex [(x, y, z) 5 (22, 46, 26); Z 5 3.24]. The
activation threshold is at P 5 0.005.
Fig. 4. (A to C) Co-
variation of activity
in brainstem regions
with activity in the
rACC (denoted by the
blue sphere) in differ-
ent pain conditions.
(A) Activity in the
rACC covaried with
activity in the PAG





greater during POP as
compared with P
[Web table 4 (27)].
(B) A similar covaria-
tion between the
rACC and the lower
pons/medulla was
observed during the PPL condition. This covariation was signiÞcantly greater during PPL as
compared with P [Web table 4 (27)]. (C) No such regressions were observed during the P
condition. The activations are presented on an SPM99-template and a more detailed image of
the brainstem indicating the approximate position of the PAG and the pons. The threshold of
activation is at P 5 0.005.
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seems to activate a more rostral part of the
orbitofrontal cortex as compared with the
general opioid effect. Because the orbitofron-
tal cortex has dense connections with both the
ACC and the brainstem (40), which have also
been implicated in placebo analgesia, we sug-
gest that these regions belong to a network
that uses cognitive cues to activate the endog-
enous opioid system.
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